						SUBSTITUTE	or PTO/SB/08A (07-05). Information Disclosure Statement by Applic Patent and Trademark Office: U.S DEPARTMENT OF COMMER	CE
` '	Substitute t	or form 1449a	APTO				COMPLETE IF KNOWN	$\overline{}$
	INFO	RMAT	ION	DISC	CLOSURE	Application Number	10/560,290	
P	YACTAT	TRATES	T DV	A IDI	LIGART 40	Filing Date	December 12, 2005	
6°	. ~ 1				/ =	First Named Inventor	H. Sings et al.	
i: his o	√ ging ₩					19 oup Art Unit	-	
A	S Just	as man	y sneeis	as ne	Cessary)	xaminer Name	- 3	
AND	CONFEET TO	1	-	of	PRADEN	Attorney Docket Number	21278P	_
							',	_

		·	U.S. P.	ATENT DOCUMENTS	
Examiner nitials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
6W	_	6166037		Budhu et al.	12/26/2000
			-		
			_		
	<u> </u>				
	_				
			-		
		-			i

				DOCUMENTS	
Examiner Initials*	Cite No.	Foreign Patent Document Office Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
KW Y		WO 02/068388		Merck & Co., Inc.	09/06/2002
		WO 02/068387		Merck & Co., Inc.	09/06/2002
		WO 03/009847		Amgem, Inc.	02/06/2003
BN		WO 02/067869		Merck & Co., Inc.	09/06/2002

Examiner: Initial If reference considered, whether or not cisation is in conformance with MPEP 600. Draw line through cluston if not in conformance and and considered. Include copy of this from with east communication to applicant.

SEND TO: Compare generated from 105 form" (IDS Falder), Mort & Co., Inc., 7/11/2003).

					Patent and Trademark Office, U.S DEPARTMENT OF COMMERCE		
Substitute for form 1449B/PTO				COMPLETE IF KNOWN			
	NFORMATION	DIS	CLOSURE	Application Number	10/560,290		
	TATEMENT BY		DI ICANE	Filing Date	December 12, 2005		
3	IAIEMENI BY	Ar	PLICANI	First Named Inventor	H. Sings et al.		
				Group Art Unit			
(use as many sheets as necessary)				Examiner Name	-		
heet	2	of	3	Attorney Docket Number	21278P		

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
AUT*	AA	Kopelman, Nature, Vol. 404 (2000), pp. 635-643, "Obesity as a medical problem"				
	ΑВ	Huszar et al., Cell, Vol. 88 (1997), pp. 131-141, "Targeted disruption of the melanocortin-4 receptor results in obesity in mice"				
	AC	Kask et al., Biochem. & Biophys. Res. Comm., Vol. 245 (1998), pp. 90-93, "Selected antagonist for the melanocortin 4 receptor (HSO014) increases food intake in free-feeding rats"				
	ΑD	Chen et al., Cell, Vol. 91' (1997), pp. 789-798; "Exocrine gland dysfunction in MC5-R-deficient mice"				
	AE	Giraudo et al., Brain Res., Vol. 809 (1998), pp. 302-306, "Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands"				
	AF	Hill et al. Science, Vol. 280 (1998), pp. 1371-1374, "Environmental contributions to the obesity epidemic"				
	AG	Corcos et al., Society for Neuroscience Abstracts, Vol. 23 (1997), Abstract No. 267.9, p. 673, "HP 228 is a potent agonist of melanocortin receptor 4, and significantly attenuates obesity and diabetes in Zucker fatty rats"				
	АН	Peptides: Frontiers of Peptide Science, Proceedings of the 15th American Peptide Symposium, June 14-19, 1997, Nashville, TN				
	ΑI	Wessels et al., J. of Urology, Vol. 160 (1998), pp. 389-393, "Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction"				
	AJ	Dorr et al., Life Sciences, Vol. 58, No. 20 (1996), pp. 1777-1784, "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study"				
	AK	Wessells et al., Urology, Vol. 56 (2000), pp. 641-646, "Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction"				
	AL	Graul, Drugs News & Perspectives, Vol. 9 (1996), pp. 572-575, "Latest findings on the diagnosis and treatment of erectile dysfunction"				
	АМ	Dinsmore et al., Brit. Med. J., Vol. 318 (1999), pp. 387-390, "ABC of sexual health — erectile dysfunction"				
	AN	Gingell et al., Exp. Opin. Ther. Patents, Vol. 9 (1999), pp. 1689-1696, "Emerging pharmacological therapies for erectile dysfunction"				
ŀm/	AO	Yoram et al., Current Opinion in Urology, Vol. 7 (1997), pp. 349-353, "Oral pharmacotherapy in erectile dysfunction"				

Examiner Signature Examiner: Initial if reference considered, whether or not clustion is in conformance with MPEP 609. Draw line through cluston if not in this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Compare generated for

Approved for use through 7/31/2006, OMB 0651-0031 SUBSTITUTE for PTO/SB/03A (07-05). Information Disclosure Statement by Applicant Patent and Trademark Office, U.S DEPARTMENT OF COMMERCE

COMPLETE IF KNOWN

INFORMATION DISCLOSURE					Application Number	10/560,290			
STATEMENT BY APPLICANT				DI ICANT	Filing Date	December 12, 2005			
STATEMENT BY APPLICANT					First Named Inventor	H. Sings et al.			
	,			,	Group Art Unit				
	(use a	s many sheets	as r	ecessary)	Examiner Name				
Sheet	heet 3 of		of	3	Attorney Docket Number	21278P			
			-	NON PATENT	LITERATURE DOCUM	MENTS			
Examiner Initials*	Cite No.		ŀ	nclude name of the author,	title, date, page(s), volume-issu	ue number(s) and place of publication.			
All	AP Heaton et al., Int'l J. of Impotence Res., Vol. 9 (199 for erectile dysfunction: an evolutionary imperative					121, "A therapeutic taxonomy of treatments			
7	AQ	Budhu et al., Database Caplus on STN No. 130:223167 (1999), "Preparation of piperidinylpyrrolidins as modulators of chemokine receptor activity"							
MY	AR Goulet et al., Database Caplus on STN No. 137:216872 (2002), " 1-((aminocycloalkyl)carbonyl)piperidines, as melanocortin-4 rece								
						1.77			

Substitute for form 1449B/PTO

Examiner Signature	Date Considered	10/1/00

"Examine: minut If reference considered, whether or not citation is in conformance with MPEP 600. Draw line through ritation if not in conformance spid not considered. Include copy of this form with next communication in supplication.

SEND TO: Communication of Parlents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated term* 105 Form* (IDS Folder), Merit & Co., Inc., 7/11/2005.